Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.91 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.91 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.64 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | DHODH | Q02127 | 2/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18540811 | 0.95 | CYP4A11 (1.00) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL31752933 | 0.94 | CYP4A11 (0.97) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL46931 | 0.90 | CYP4A11 (1.00) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL70173 | 0.88 | CYP4F2 (0.83) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL10606812 | 0.87 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL1792728 | 0.87 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL19078986 | 0.86 | CYP4A11 (0.78) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL6614812 | 0.86 | CYP4A11 (0.73) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL8921794 | 0.86 | CYP4A11 (0.73) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL5725416 | 0.86 | CYP4A11 (0.73) | CYP4A11CYP4F2LOXL2SLC7A5DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727355-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| WO-2020162612-A1 | PYRIDINE COMPOUND SUBSTITUTED BY HETEROARYL | 大正製薬株式会社 | 2020-08-13 | — | — | WO | disclosed |
| WO-2020162612-A1 | PYRIDINE COMPOUND SUBSTITUTED BY HETEROARYL | 大正製薬株式会社 | 2020-08-13 | — | — | WO | disclosed |
| CN-111491623-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| CN-100354264-C | 5-substituted isoquinoline derivatives and drugs containing them | ASAHI KASEI PHARMA CORP (JP) | 2007-12-12 | — | — | CN | disclosed |
| US-7094789-B2 | 5-substituted isoquinoline derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-08-22 | — | — | US | disclosed |
| CN-1668600-A | 5-substituted isoquinoline derivatives | ASAHI KASEI PHARMA CORP (JP) | 2005-09-14 | — | — | CN | disclosed |
| EP-1541559-A1 | 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20050020623-A1 | 5-Substituted isoquinoline derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-0235452-B1 | ORGANIC COMPOUNDS AND THEIR PHARMACEUTICAL USE | LILLY INDUSTRIES LIMITED (GB) | 1992-03-18 | — | — | EP | disclosed |
| EP-0162208-B1 | NOVEL N-SUBSTITUTED 3,4-DIHYDROPYRIMIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS | SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) | 1989-11-23 | — | — | EP | disclosed |
| US-4845110-A | Organic compounds and their pharmaceutical use | LILLY INDUSTRIES LIMITED (GB) | 1989-07-04 | — | — | US | disclosed |
| EP-0235452-A2 | Organic compounds and their pharmaceutical use | LILLY INDUSTRIES LIMITED (GB) | 1987-09-09 | — | — | EP | disclosed |
| US-4683234-A | HYPOTENSIVE AGENTS, ANTI-ANGINA | SUNTORY LIMITED (JP) | 1987-07-28 | — | — | US | disclosed |
| EP-0162208-A2 | Novel N-substituted 3,4-dihydropyrimidine derivatives, processes for preparing them and pharmaceutical compositions | SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) | 1985-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020623-A1 | 5-Substituted isoquinoline derivatives | MYLK, MYLK2, MYL12A | CYP4A11 3545/4885CYP4F2 4148/4885LOXL2 2022/4885 |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | CYP4A11 355/4885CYP4F2 107/4885LOXL2 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.